CA2438930A1 - Treatment of tics, tremors and related disorders - Google Patents
Treatment of tics, tremors and related disorders Download PDFInfo
- Publication number
- CA2438930A1 CA2438930A1 CA002438930A CA2438930A CA2438930A1 CA 2438930 A1 CA2438930 A1 CA 2438930A1 CA 002438930 A CA002438930 A CA 002438930A CA 2438930 A CA2438930 A CA 2438930A CA 2438930 A1 CA2438930 A1 CA 2438930A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- disorder
- compound
- mammal
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010044565 Tremor Diseases 0.000 title claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 36
- 208000035475 disorder Diseases 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 77
- 208000016686 tic disease Diseases 0.000 claims abstract description 32
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract description 31
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims abstract description 30
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 30
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 30
- 230000001773 anti-convulsant effect Effects 0.000 claims abstract description 28
- 229960003965 antiepileptics Drugs 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 22
- 208000000269 Hyperkinesis Diseases 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 60
- -1 pyrrolidone compound Chemical class 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 19
- 229960004002 levetiracetam Drugs 0.000 claims description 18
- 150000002431 hydrogen Chemical group 0.000 claims description 17
- 230000003252 repetitive effect Effects 0.000 claims description 16
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 14
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 14
- 229960004526 piracetam Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000006517 essential tremor Diseases 0.000 claims description 5
- 208000015879 Cerebellar disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 claims description 4
- 229960003389 pramiracetam Drugs 0.000 claims description 4
- GOWRRBABHQUJMX-MRVPVSSYSA-N Fasoracetam Chemical compound C1CCCCN1C(=O)[C@H]1CCC(=O)N1 GOWRRBABHQUJMX-MRVPVSSYSA-N 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims description 3
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010016212 Familial tremor Diseases 0.000 claims description 2
- 206010022520 Intention tremor Diseases 0.000 claims description 2
- 206010071390 Resting tremor Diseases 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 229960000793 aniracetam Drugs 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 229950010008 fasoracetam Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229950010963 nebracetam Drugs 0.000 claims description 2
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 claims description 2
- 229950004663 nefiracetam Drugs 0.000 claims description 2
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001227 oxiracetam Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 206010072413 Action tremor Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 abstract description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 19
- 208000002033 Myoclonus Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 208000016285 Movement disease Diseases 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000012661 Dyskinesia Diseases 0.000 description 8
- 208000008234 Tics Diseases 0.000 description 7
- 230000003483 hypokinetic effect Effects 0.000 description 6
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 6
- 208000015592 Involuntary movements Diseases 0.000 description 5
- 230000001660 hyperkinetic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000013716 Motor tics Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940125681 anticonvulsant agent Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 206010018762 Grunting Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- RHAGCPFKFQCWSY-UHFFFAOYSA-N 1-[4-[[di(propan-2-yl)amino]methylamino]-3-oxobut-1-en-2-yl]pyrrolidin-2-one Chemical compound CC(C)N(C(C)C)CNCC(=O)C(=C)N1CCCC1=O RHAGCPFKFQCWSY-UHFFFAOYSA-N 0.000 description 1
- STDUAJGQCNHVFQ-UHFFFAOYSA-N 2-(3-hydroxy-2-oxopyrrolidin-1-yl)acetamide Chemical compound NC(=O)CN1CCC(O)C1=O STDUAJGQCNHVFQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003547 Asterixis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010010964 Coprolalia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019191 Head banging Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038583 Repetitive speech Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 208000002161 echolalia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 201000002904 focal dystonia Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000002886 generalized dystonia Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000023515 periodic limb movement disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 201000002899 segmental dystonia Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000013623 stereotypic movement disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27098701P | 2001-02-23 | 2001-02-23 | |
| US60/270,987 | 2001-02-23 | ||
| PCT/US2002/005189 WO2002067931A1 (en) | 2001-02-23 | 2002-02-22 | Treatment of tics, tremors and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2438930A1 true CA2438930A1 (en) | 2002-09-06 |
Family
ID=23033711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002438930A Abandoned CA2438930A1 (en) | 2001-02-23 | 2002-02-22 | Treatment of tics, tremors and related disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040116505A1 (OSRAM) |
| EP (1) | EP1379236A4 (OSRAM) |
| JP (1) | JP2004523557A (OSRAM) |
| AU (1) | AU2002245486B2 (OSRAM) |
| CA (1) | CA2438930A1 (OSRAM) |
| WO (1) | WO2002067931A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242671A1 (en) * | 2001-10-08 | 2004-12-02 | Renee Grimee | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| US20070259859A1 (en) * | 2006-05-04 | 2007-11-08 | De Bruin Natasja M W J | Muscarinic agonists to treat impulse control disorders |
| ES2336275T3 (es) * | 2006-05-04 | 2010-04-09 | Solvay Pharmaceuticals B.V. | Agonistas muscarinicos para tratar trastornos del control de impulsos. |
| EP3260118B1 (en) | 2008-10-16 | 2021-03-24 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US20110212928A1 (en) * | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2609220B1 (en) | 2010-08-24 | 2018-06-27 | The Children's Hospital of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN103044307A (zh) * | 2013-01-24 | 2013-04-17 | 吉林三善恩科技开发有限公司 | 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法 |
| CN103073477A (zh) * | 2013-01-24 | 2013-05-01 | 吉林三善恩科技开发有限公司 | 以3,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法 |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| KR20170048313A (ko) * | 2014-06-02 | 2017-05-08 | 케토젠 인코포레이티드 | 발작 및 기타 중추신경계 장애 및 병증 치료용 화합물 |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| PL3922249T3 (pl) * | 2015-09-08 | 2024-07-29 | The Children's Hospital Of Philadelphia | Diagnozowanie i leczenie zaburzeń lękowych |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4355027A (en) * | 1977-11-02 | 1982-10-19 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering piracetam and choline |
| CH657527A5 (de) * | 1980-02-13 | 1986-09-15 | Ciba Geigy Ag | Verwendung von zentralnervoes-wirksamen verbindungen in einem mittel, welches zur verhinderung oder linderung von nebenwirkungen bestimmt ist. |
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| JPH0829140B2 (ja) * | 1987-04-17 | 1996-03-27 | 開成工業株式会社 | 末▲梢▼循環機能障害診断用皮フ温測定装置 |
| US6107492A (en) * | 1998-05-08 | 2000-08-22 | Ucb, S.A. | Process for the preparation of levetiracetam |
| RO121085B1 (ro) * | 1999-12-01 | 2006-12-29 | Ucb, S.A., | Utilizarea levetiracetamului, în tratamentul bolilor sistemului nervos central |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
-
2002
- 2002-02-22 JP JP2002567298A patent/JP2004523557A/ja active Pending
- 2002-02-22 AU AU2002245486A patent/AU2002245486B2/en not_active Ceased
- 2002-02-22 CA CA002438930A patent/CA2438930A1/en not_active Abandoned
- 2002-02-22 WO PCT/US2002/005189 patent/WO2002067931A1/en not_active Ceased
- 2002-02-22 EP EP02713649A patent/EP1379236A4/en not_active Withdrawn
- 2002-02-22 US US10/468,937 patent/US20040116505A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002245486B2 (en) | 2006-11-16 |
| WO2002067931A1 (en) | 2002-09-06 |
| US20040116505A1 (en) | 2004-06-17 |
| JP2004523557A (ja) | 2004-08-05 |
| EP1379236A4 (en) | 2009-01-21 |
| EP1379236A1 (en) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002245486B2 (en) | Treatment of tics, tremors and related disorders | |
| AU2002245486A1 (en) | Treatment of tics, tremors and related disorders | |
| Winger et al. | Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| AU6895800A (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
| CN102512406A (zh) | 用于治疗认知障碍的α-氨基酰胺衍生物 | |
| US20100267835A1 (en) | Methods of treating disorders of trigeminalvascular activation | |
| AU2009201746A1 (en) | [(2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | |
| CA2458855A1 (en) | Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| AU772156B2 (en) | Compositions comprising GABA analogs and caffeine | |
| JP2004523557A5 (OSRAM) | ||
| CN1160347A (zh) | 吲哚衍生物在治疗皮肤病、外周神经病、关节炎、头痛、口面疼痛、过敏或慢性导气管阻塞病、青光眼及眼部炎症中的应用 | |
| DE69738320T2 (de) | Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch | |
| DE69623767T2 (de) | Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus | |
| AU2004226805A1 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| Rogers et al. | P. 4.022 Donepezil is well tolerated at clinically effective doses for the treatment of alzheimer's disease (AD) | |
| MXPA04008574A (es) | Metodos para prevenir y tratar neuropatia periferica al administrar desmetilselegilina. | |
| Rogers et al. | P. 4.021 Donepezil improves cognition in patients with mild to moderate AD: Results of ADAS-COG analysis in a 30-week phase III study | |
| WO2019083409A1 (ru) | Комбинация и набор с анксиолитическим действием | |
| Bazin et al. | P. 4.019 Memory impairment evaluation and alzheimer's disease treatment: A pluridisciplinary experience concerning one hundred patients | |
| HK1064609B (en) | 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino alkyl -acid derivatives for the treatment of pain | |
| MXPA97008875A (en) | Use of pyrrolidine derivatives in the preparation of medicines intended for the alcohol treatment | |
| AU2002353792A1 (en) | ((2-(amino-3,4-dioxo-1cyclobuten-1-YL)amino)alkyl)-acid derivatives for the treatment of pain | |
| EP1547597A2 (en) | Use of adatanserin for the treatment of neurodegenerative conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |